Postmortem lung biopsies from four patients with COVID-19 at a tertiary hospital in Cape Town, South Africa by Bruce-Brand, C et al.
1195       December 2020, Vol. 110, No. 12
RESEARCH
An outbreak of a novel coronavirus caused by the severe acute 
respiratory syndrome coronavirus 2 (SARS-CoV-2) occurred 
in Wuhan, China, in late 2019. The World Health Organization 
designated the disease in humans as coronavirus disease 2019 
(COVID-19) and subsequently declared a global pandemic.[1] At the 
time of writing (30 August 2020), >14 000 deaths due to COVID-19 
had been documented in South Africa (SA).[2] The first description 
of the histological findings in pulmonary tissue in COVID-19 (in 
lobectomy specimens removed for primary carcinomas of the lung) 
showed oedema, type 2 pneumocyte hyperplasia, proteinaceous 
exudates, a patchy chronic inflammatory infiltrate, multinucleated 
giant cells and suspected viral inclusions within pneumocytes.[3] 
Since this publication, numerous autopsy and postmortem biopsy 
studies have described histopathological features of the severe acute 
respiratory syndrome caused by this virus. These findings include 
diffuse alveolar damage, organising pneumonia, superimposed acute 
bronchopneumonia, type 2 pneumocyte hyperplasia, squamous 
metaplasia, congestion and fibrin thrombi and have been well 
summarised in a recent review by Al Nemer.[4-11] The performance 
of hospital autopsies on confirmed COVID-19 cases has not been 
authorised in our setting, owing to safety concerns for mortuary 
staff and a lack of appropriately equipped mortuaries. There have 
therefore been no published reports of the histopathology findings 
from SA to date. Postmortem biopsies are quick, easy to perform 
and relatively safe compared with full autopsies and provided the 
only means of obtaining tissue for histopathology assessment in 
our setting.
Objectives
We hypothesised that by performing standardised lung-targeted 
postmortem biopsies we could determine the cause of death in 
patients who died due to complications of COVID-19 in an intensive 
care unit (ICU) in Cape Town, SA. We also aimed to describe the 
clinical and histological findings of all included cases.
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Background. An outbreak of a novel coronavirus in China in late 2019 has resulted in a global pandemic. The virus (SARS-CoV-2) causes a 
severe acute respiratory syndrome and had been responsible for >14 000 deaths in South Africa (SA) at the time of writing, 30 August 2020. 
Autopsies in our setting have not been prioritised owing to the infective risks for staff, resulting in a lack of information on the histopathology of 
the disease in the SA setting. Postmortem biopsies are relatively quick and easy to perform and reduce the infective risk posed by full autopsies.
Objectives. To determine whether postmortem biopsies of lung tissue could be used to determine cause of death in lieu of full autopsies in 
patients dying from COVID-19.
Methods. We performed postmortem biopsies of lung tissue on 4 patients with SARS-CoV-2 confirmed by reverse transcriptase polymerase 
chain reaction who died in the Tygerberg Hospital (Cape Town, SA) intensive care unit (ICU) in June - July 2020, in order to determine 
their cause of death. The biopsies were performed in the ICU with the necessary personal protective equipment within 2 hours after death. 
Clinical information was obtained from the hospital records and the histopathology was reviewed by two consultant histopathologists. 
Microbiology and electron microscopy were also performed on this tissue.
Results. All 4 patients were aged >50 years and had multiple comorbidities. Pulmonary pathology was present in only 3 cases, and the 
findings were surprisingly heterogeneous. One case demonstrated several findings including diffuse alveolar damage, extensive fibrin 
thrombi in pulmonary arteries with pulmonary infarction, organising pneumonia and bronchopneumonia. Other findings included type 
2 pneumocyte hyperplasia, intra-alveolar macrophages and squamous metaplasia. An organising pneumonia was present in 2 other cases, 
although these findings were not deemed to be severe enough to be the cause of death. Fibrin thrombi were present in pulmonary arteries 
of 3 cases. One case showed no significant acute pulmonary pathology. The cause of death could only be determined in 1 case.
Conclusions. The pulmonary findings we observed are in keeping with those described in the international literature. However, the 
pathology was surprisingly heterogeneous between cases, and was only deemed severe enough to be the cause of death in 1 of 4 cases. While 
lung-targeted, standardised postmortem biopsies may be safe, easy to perform and provide useful insights into the disease, they are not 
suitable to replace full autopsies in determining cause of death.
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Methods
Postmortem samples were taken from 4 adult patients who tested 
positive for SARS-CoV-2 by reverse transcriptase polymerase chain 
reaction and subsequently died in the Tygerberg Hospital ICU 
between June and July 2020 as a result of COVID-19. Verbal delayed 
proxy consent was obtained from the families of these patients. 
Postmortem biopsies were performed in the ICU by one of the 
treating doctors within 2 hours after death. Appropriate personal 
protective equipment as dictated by the hospital safety guidelines was 
worn by those performing the biopsies. Core needle biopsies were 
taken from each lung lobe (without imaging guidance) followed by 
a single open lung biopsy of the right lung, in the mid-axillary line 
and 4th or 5th intercostal space. Each specimen was placed into an 
individually labelled specimen jar and macroscopically assessed for 
adequacy by a member of the research team. The specimens for 
histopathology were fixed in 10% buffered formalin and processed in 
the histopathology laboratory after appropriate fixation. Tissue was 
also submitted for microbiology (one core from the upper lobe of 
each lung in normal saline) and electron microscopy (one fragment 
from the lower lobe of each lung in glutaraldehyde). The histology 
was assessed by two consultant histopathologists at the National 
Health Laboratory Service. Clinical information such as age, gender, 
comorbidities, duration of illness and ICU admission, methods of 
ventilation and treatment (antimicrobials, anticoagulant therapy 
and corticosteroid therapy) were captured from the hospital records. 
Ethical approval for this study was provided by the Stellenbosch 
University Health Research Ethics Committee.
Findings
Clinical characteristics
The 4 patients were 3 women, all aged 58 years, and 1 man, aged 
65 years. All had comorbidities, including hypertension and obesity 
(4/4), type 2 diabetes mellitus (3/4), atrial fibrillation (1/4), epilepsy 
(1/4) and hypercholesterolaemia (1/4). None of the patients had 
HIV infection. The duration of ICU admission ranged from 2 days 
to 1 week, with all patients initially receiving ventilation in the form 
of high-flow nasal oxygen. Three were ultimately intubated and 
mechanically ventilated. All 4 had elevated acute-phase reactants and 
raised D-dimers. Treatment included antimicrobials, anticoagulant 
therapy (clexane and/or aspirin) and corticosteroid therapy, and 
details are presented with the summarised clinical features in Table 1.
Histology
The histopathology findings are summarised in Table 2. Only 1 
of the 4 patients demonstrated features of diffuse alveolar damage 
with hyaline membranes (Fig. 1). This patient (patient 3) also 
Table 1. Clinical features of 4 patients with COVID-19
Clinical parameters Patient 1 Patient 2 Patient 3 Patient 4
Age (years) 58 58 65 58















Duration of symptoms prior to admission (days) 3 2 3 7
Duration of ICU admission (days) 7 2 5 3
Method of ventilation (days)
HFNC 7 1 1 2
NIV 0 0 0 0
IPPV 0 1 4 1












Clexane Yes (therapeutic) Yes (therapeutic) Yes (therapeutic) No
Aspirin No No Yes Yes
Corticosteroid use (type) Dexamethasone Dexamethasone Dexamethasone Dexamethasone
Full blood count
WCC (× 109/L) 16.2 14.32 11.4 34.4
Hb (g/dL) 9.2 14.2 10.8 10.2
Plt (× 109/L) 204 95 98 367
Neut (× 109/L) 13.9 12.76 10.4 30.4
Lymph (× 109/L) 1.54 1.03 0.48 2.27
Acute-phase markers
CRP (mg/L) 29 345 434 123
PCT (µg/L) 1.03 51.64 5.45 0.38
D-dimer (mg/L) 0.93 2.04 17.6 1.21
HPT = hypertension; DM = diabetes mellitus; AF = atrial fibrillation; HCL = hypercholesterolaemia; ICU = intensive care unit; HFNC = high-flow nasal cannula; NIV = non-invasive ventilation; 
IPPV = intermittent positive-pressure ventilation; WCC = white cell count (normal 3.9 - 12.6); Hb = haemoglobin (normal 12.0 - 15.0); Plt = platelet count (normal 186 - 454);  
Neut = neutrophils (normal 1.6 - 8.3); Lymph = lymphocytes (normal 1.4 - 4.5); CRP = C-reactive protein (normal <10); PCT = procalcitonin (˃10 suggestive of severe systemic infection); 
D-dimer normal 0.00 - 0.25. Blood results shown are the most recent results available.
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demonstrated extensive fibrin thrombi within pulmonary arteries 
(Fig. 2A), capillary congestion and pulmonary infarction (Fig.  3), 
and had markedly elevated D-dimer levels of 17.6 mg/L. An 
organising pneumonia as well as a bronchopneumonia were present 
in this case (Figs 4A and 5). No organisms were cultured. Patients 
1 and 4 also demonstrated organising pneumonia, although these 
findings were not marked (Fig. 4B). Squamous metaplasia was 
only seen in 1 case (patient 1 – Fig. 6). Fibrin thrombi were seen 
in pulmonary arteries in 3 cases (patients 1, 3 and 4), all of whom 
had received anticoagulant therapy (Fig, 2B). One case had no 
acute pulmonary findings (patient 2), but the background lung 
showed extensive carbon pigment deposition and thickened pleura. 
Electron microscopy was performed on all 4 cases, but viral particles 
could not be demonstrated. No bacterial or fungal organisms were 
cultured in any of the cases.
Discussion
We describe the pulmonary histopathological findings in 4 cases of 
fatal COVID-19 obtained though postmortem biopsies of lung tissue, 
which demonstrated varied pathology between cases, including 
interstitial lymphocytes, intra-alveolar macrophages and oedema, 
multinucleated giant cells and type 2 pneumocyte hyperplasia 
(Fig.  7). The clinical parameters of these patients are in keeping 
with the expected patient profile described so far in fatal COVID-
19, including the presence of multiple comorbidities and older age. 
However, in 3 of the 4 cases, the pulmonary findings were deemed of 
insufficient severity to be attributed as the cause of death, with only 
mild changes observed in 2 cases and no significant acute pulmonary 
pathology seen in 1. A limited number of postmortem lung biopsies 
therefore does not reliably demonstrate the cause of death in our 
series of patients dying from COVID-19 in an ICU.
The histopathology of the pulmonary tissue showed changes 
sufficient to be deemed the cause of death in only 1 patient (patient 
3); these included diffuse alveolar damage, type 2 pneumocyte 
hyperplasia, extensive fibrin thrombi, capillary congestion, organising 
pneumonia and bronchopneumonia. These findings have been 
described in the setting of COVID-19. In an autopsy series of 21 
patients in Switzerland, the most prominent findings described 
included exudative diffuse alveolar damage, pulmonary capillary 
congestion and reactive pneumocytes.[10] Additionally, microthrombi, 
pulmonary embolism and bronchopneumonia were seen in a subset 
of cases.[10]
We noted multinucleated giant cells (Fig. 8), also described 
in other studies, which have been shown to be syncytial type 
2 pneumocytes (positive with thyroid transcription factor 1 
immunohistochemistry). [10] Squamous metaplasia within alveoli, an 
Table 2. Summary of histological findings
Patient 1 Patient 2 Patient 3 Patient 4
Acute inflammation (neutrophils) Absent Absent Present Absent
Interstitial lymphocytes Absent Absent Present Present
Intra-alveolar macrophages Present, focal Absent Present Present
Type 2 pneumocyte hyperplasia Absent Absent Present Present
Multinucleated giant cells Absent Absent Present Present
Intra-alveolar oedema Present Absent Present Absent
Interstitial oedema Absent Absent Absent Absent
Squamous metaplasia Present Absent Absent Absent
Fibrin thrombi
Pulmonary arteries Present, focal Absent Present, extensive Present
Pulmonary veins Absent Absent Absent Absent
Congestion
Pulmonary arteries Absent Absent Absent Absent
Pulmonary veins Absent Absent Absent Absent
Capillaries Absent Absent Present Absent
Alveolar haemorrhage Absent Absent Present Absent
Hyaline membranes Absent Absent Present Absent
Collapsed alveoli Absent Absent Absent Absent
Pleural changes Absent Marked thickening Absent Absent
Arterial hyalinisation Absent Absent Absent Present
Organising pneumonia Present Absent Present Present





Fig. 1. Alveolar spaces are lined by thick hyaline membranes (arrow). 
The interstitium is oedematous and scattered lymphocytes are present 
(haematoxylin and eosin × 200).
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unusual finding, was seen in 1 case (Fig. 6). This was described in a 
few cases of COVID-19 in the Northern Italy series[12] and has been 
described in other viral infections such as severe acute respiratory 
syndrome (SARS), particularly with a duration of illness beyond 
14 days.[13,14] Interestingly, hyaline membranes were not prominent in 
3 of the 4 cases, and alveolar collapse was not observed.
Evidence suggests that COVID-19 causes an intense inflammatory 
reaction marked by upregulation of cytokines which result in lung 
Fig. 5. This core of lung tissue demonstrates an acute bronchopneumonia 
with extensive accumulation of neutrophils within alveolar spaces (arrows) 
(haematoxylin and eosin × 200).
A
B
Fig. 2. A: A fibrin thrombus is present within a pulmonary artery (arrow) 
(haematoxylin and eosin × 100). B: A fibrin thrombus in a pulmonary 
artery (arrow). The background lung tissue is relatively normal in this case 
(haematoxylin and eosin × 200).
Fig. 3. The lung parenchyma adjacent to the thrombus in Fig. 2A is infarcted. 
The cellular detail of the cells lining the alveolar spaces is lost and there is 




Fig. 4. A: Organising pneumonia is present. The alveolar spaces are filled 
with fibromyxoid material (arrows) (haematoxylin and eosin × 100). B: This 
lung tissue demonstrates plugs of fibromyxoid material within alveolar 
spaces (arrows). The background lung appears relatively well preserved 
(haematoxylin and eosin × 100).
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injury.[15,16] Corticosteroid therapy modulates such host responses and 
has been shown to reduce hospital mortality in patients with severe 
COVID-19.[17] All 4 patients received corticosteroid therapy from the 
time of admission to the ICU. The presence of organising pneumonia 
in 3 cases and the absence of diffuse alveolar damage in 2 of these 
may be explained by the effectiveness of the corticosteroid therapy.
Much has been written regarding the coagulopathy and endothelial 
damage caused by COVID-19.[18] In our patients, 3 of the 4 had fibrin 
thrombi in vessels with elevated D-dimer levels, despite all being on 
anticoagulant therapy. Patient 3 had a markedly elevated D-dimer 
reading (17.6 mg/L) and showed pulmonary infarction, probably 
due to the extensive fibrin thrombi seen. The finding of pulmonary 
infarction has not been described in COVID-19 to our knowledge, 
but has been described in SARS-CoV (severe acute respiratory 
syndrome coronavirus).[13,14]
Bronchopneumonia was observed in 1 case, and 2 cases showed 
markedly raised procalcitonin values, yet no bacterial or fungal 
organisms were observed or cultured. Since bronchopneumonia 
may be patchy, there may be sampling bias with performance of core 
needle biopsies. All 4 patients had received antibiotic therapy, which 
could potentially have sterilised samples prior to collection. No viral 
particles could be seen on electron microscopy within pneumocytes, 
macrophages or endothelial cells.
Study limitations
This series has a number of limitations, first being the small sample 
size, which limits our ability to draw conclusions. Despite the high 
mortality figures, this small sample reflects issues regarding the local 
policies for obtaining postmortem specimens. Secondly, owing to 
safety concerns, full postmortem examinations were not authorised, 
and lung biopsies remained the only option available to researchers. 
Despite samples being obtained from multiple lobes of both lungs 
within 2 hours of death to minimise tissue autolysis, sampling error 
may still have occurred. Sampling was done blindly without imaging 
guidance and abnormal areas of lung were therefore not specifically 
targeted. Lack of inclusion of patients with HIV infection limits the 
extrapolation of these findings to immunocompromised individuals.
Despite these limitations, the histological findings in these cases 
were remarkably varied between patients, despite phenotypically 
similar clinical disease profiles. In 3 cases the pulmonary findings 
were deemed mild, and death in these cases was probably not due 
to the observed pulmonary complications of COVID-19. The lack 
of significant pulmonary findings in 3 cases emphasises the need for 
performance of full medical autopsies for patients dying of COVID-19, 
in order to gain better understanding of the spectrum of pathology 
and causes of death, with a view to improving outcomes. More 
histopathology specimens are specifically needed in HIV-positive 
cases, which may not be the same as in immunocompetent patients.
Conclusions
The spectrum of pulmonary pathology seen in our setting in patients 
dying from complications of COVID-19 includes diffuse alveolar 
damage, organising pneumonia, superimposed bronchopneumonia, 
fibrin thrombi, type 2 pneumocyte hyperplasia and squamous 
metaplasia. These findings are in keeping with those described in the 
international literature. However, the pulmonary findings were severe 
enough to explain the cause of death in only 1 of the 4 cases and 
were heterogeneous between cases. While performance of a limited 
prespecified number of postmortem lung biopsies may reduce safety 
concerns in the setting of a highly infectious disease, the pathology 
and treatment-induced changes are too varied to be captured by 
such an approach. This varied pathology highlights the need for 
performance of full autopsies in order to accurately determine the 
cause of death in patients dying with COVID-19 and the need for 
availability of appropriate facilities to conduct such autopsies.
Fig. 6. Squamous metaplasia of the alveolar spaces is evident (arrow) 
(haematoxylin and eosin × 100).
Fig. 7. Type 2 pneumocyte hyperplasia is present (arrow). The interstitium 
is expanded with oedema, and lymphocytes and multinucleated cells are 
present (haematoxylin and eosin × 200).
Fig. 8. The multinucleated cells at higher magnification (arrow). These 
cells are positive for thyroid transcription factor 1, indicating that they are 
pneumocytes rather than macrophages (haematoxylin and eosin × 400).
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